Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Bilibili Secondary Listing Early Look - Will Probably Be More like JD and NetEase

ECM Weekly (14 February 2021) - Youran Dairy, Bairong, Joinn Lab, Bilibili HK,

ECM Weekly (21 February 2021) - Tencent Lock-Up Expiry, SciClone Pharma, Joinn Lab, Bairong, Betta

Bilibili IPO Review - A Vibrant Community but Longer Track Record Is Needed

Bilibili IPO Valuation: A Grand Risk Seems in Order

IQiyi IPO: A Short-Term Bet Before Wait-And-See

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Bilibili announced a USD 300 million share placement and a USD 300 million convertible note placement after market close on Monday. This is the first major placement since Bilibili's IPO in March 2018. In this insight, we will provide our thoughts on the deal and score the deal in our ECM Framework. </p>

Bilibili announced a USD 300 million share placement and a USD 300 million convertible note placement after market close on Monday. This is the first major placement since Bilibili's IPO in March 2018. In this insight, we will provide our thoughts on the deal and score the deal in our ECM Framework. 

Bilibili

Bilibili Placement: Momentum Bodes Well